

Philippe Saiag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5506467/publications.pdf>

Version: 2024-02-01

182
papers

9,134
citations

53794

45
h-index

45317

90
g-index

306
all docs

306
docs citations

306
times ranked

9708
citing authors

#	ARTICLE	IF	CITATIONS
1	Monitoring of plasma concentrations of dabrafenib and trametinib in advanced BRAFV600 melanoma patients. <i>Annales De Dermatologie Et De Venereologie</i> , 2022, 149, 32-38.	1.0	4
2	Impact of the French COVID-19 pandemic lockdown on newly diagnosed melanoma delay and severity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	22
3	Investigation of the RB1-SOX2 axis constitutes a tool for viral status determination and diagnosis in Merkel cell carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 1239-1254.	2.8	6
4	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 236-255.	2.8	102
5	Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9529-9529.	1.6	0
6	Efficacy and tolerance of systemic therapies in metastatic melanoma of unknown primary versus known cutaneous: A multicenter retrospective study from the MelBase French Cohort.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9556-9556.	1.6	0
7	Association of baseline corticosteroid treatment with outcomes for patients (pts) with BRAF-mutant melanoma brain metastases (MBMs) in COMBI-MB treated with dabrafenib and trametinib (DT).. <i>Journal of Clinical Oncology</i> , 2022, 40, e21546-e21546.	1.6	1
8	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline " Update 2022. <i>European Journal of Cancer</i> , 2022, 171, 203-231.	2.8	51
9	Development of a core outcome set for cutaneous squamous cell carcinoma trials: identification of core domains and outcomes*. <i>British Journal of Dermatology</i> , 2021, 184, 1113-1122.	1.5	7
10	Narrow resection margins are not associated with mortality or recurrence in patients with Merkel cell carcinoma: A retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 921-929.	1.2	10
11	Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-programmed cell death receptor-1 monoclonal antibodies. <i>British Journal of Dermatology</i> , 2021, 184, 746-748.	1.5	1
12	Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study. <i>International Journal of Cancer</i> , 2021, 148, 2789-2798.	5.1	5
13	Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data†. <i>Annals of Oncology</i> , 2021, 32, 542-551.	1.2	13
14	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	10.7	37
15	Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study). <i>EClinicalMedicine</i> , 2021, 35, 100844.	7.1	31
16	Differential gradients of efficacy of immunotherapy according to the sun-exposure pattern of the site of occurrence of primary melanoma: A multicenter prospective cohort study (MELBASE).. <i>Journal of Clinical Oncology</i> , 2021, 39, e21545-e21545.	1.6	4
17	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	10.7	224
18	Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma. <i>Cancers</i> , 2021, 13, 3042.	3.7	3

#	ARTICLE	IF	CITATIONS
19	Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma. <i>British Journal of Cancer</i> , 2021, 125, 948-954.	6.4	11
20	Efficacy, safety and factors associated with disease progression in patients with unresectable (stage) Tj ETQq0 0 0 rgBT /Overlock 10 Tf IIIb study of trametinib in combination with dabrafenib. <i>European Journal of Cancer</i> , 2021, 154, 57-65.	2.8	9
21	1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program. <i>Annals of Oncology</i> , 2021, 32, S895.	1.2	0
22	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 145-155.	1.0	4
23	Qualityâ€ofâ€life assessment in French patients with metastatic melanoma in real life. <i>Cancer</i> , 2020, 126, 611-618.	4.1	12
24	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment â€ Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	2.8	154
25	The evolving field of Dermatoâ€oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDVâ€UEMS and EORTC Cutaneous Lymphoma Task Force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2183-2197.	2.4	22
26	1121P Factors predicting overall survival (OS) and progression-free survival (PFS) in real-life: Classification and regression tree analysis of a 5-year (5Y) cohort follow-up study of advanced melanoma patients (pts) that have initiated pembrolizumab. <i>Annals of Oncology</i> , 2020, 31, S754-S755.	1.2	9
27	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020, 128, 60-82.	2.8	131
28	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	2.8	181
29	Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing antiâ€PDâ€1 monotherapy. <i>International Journal of Cancer</i> , 2020, 147, 1707-1714.	5.1	14
30	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics â€ Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158.	2.8	133
31	Does body mass index really predict the response to systemic therapies in metastatic melanoma: A multicenter study from the MelBase French National Cohort?. <i>Journal of Clinical Oncology</i> , 2020, 38, 10031-10031.	1.6	1
32	An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis. <i>Annals of Oncology</i> , 2019, 30, v542-v543.	1.2	1
33	Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600-mutant melanoma: An open label, non randomized study. <i>Annals of Oncology</i> , 2019, 30, v546.	1.2	0
34	Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival. <i>JAMA Dermatology</i> , 2019, 155, 673.	4.1	7
35	Histologic predictors of invasion in partially biopsied lentigo maligna melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1150-1152.	1.2	6
36	Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. <i>European Journal of Cancer</i> , 2019, 112, 38-46.	2.8	27

#	ARTICLE	IF	CITATIONS
37	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. <i>Melanoma Management</i> , 2019, 6, MMT33.	0.5	6
38	PCN96 COST-EFFECTIVENESS OF TREATMENT SEQUENCES FOR BRAF WILD-TYPE METASTATIC MELANOMA IN REAL LIFE IN FRANCE. <i>Value in Health</i> , 2019, 22, S454-S455.	0.3	0
39	PCN461 CHARACTERIZATION OF THE CARE PATHWAYS OF PATIENTS WITH MERKEL CELL CARCINOMA IN FRANCE. <i>Value in Health</i> , 2019, 22, S526.	0.3	0
40	Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma. <i>European Journal of Dermatology</i> , 2019, 29, 636-640.	0.6	12
41	Hyponatremia and MAP kinase inhibitors in malignant melanoma: Frequency, pathophysiological aspects and clinical consequences. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 326-331.	3.3	5
42	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. <i>Lancet Haematology</i> , 2019, 6, e48-e57.	4.6	195
43	Efficacy of hypofractionated radiotherapy (Rx) in melanoma patients who failed anti-PD-1 monotherapy: Assessing the abscopal effect.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9537-9537.	1.6	8
44	Plasma concentrations of dabrafenib and trametinib (PCD/T) monitoring in advanced BRAFV600mut melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9541-9541.	1.6	1
45	Progression and hyperprogression after anti-PD1 therapy for unresectable stage III or IV melanoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21021-e21021.	1.6	0
46	Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients. <i>Oncolmmunology</i> , 2018, 7, e1442166.	4.6	57
47	Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 294-303.	2.8	8
48	On/off dropped head syndrome: A severe adverse event after prolonged treatment with MEK inhibitor. <i>European Journal of Cancer</i> , 2018, 91, 174-176.	2.8	2
49	STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. <i>Journal of Investigative Dermatology</i> , 2018, 138, 58-67.	0.7	47
50	Concomitant radiotherapy in melanoma brain metastases using the propensity score matching within the French cohort, MelBase. <i>Annals of Oncology</i> , 2018, 29, viii444-viii445.	1.2	0
51	Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort. <i>European Journal of Cancer</i> , 2018, 105, 33-40.	2.8	38
52	Nivolumab to control molecular response in chronic myeloid leukemia. <i>Leukemia Research</i> , 2018, 72, 5-6.	0.8	2
53	Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9509-9509.	1.6	19
54	Iplimumab combined with stereotactic radiosurgery in melanoma patients with brain metastases: A multicenter, open label, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9520-9520.	1.6	3

#	ARTICLE	IF	CITATIONS
55	Impact of simultaneous radiotherapy in melanoma patients treated with pembrolizumab in the French early access program.. Journal of Clinical Oncology, 2018, 36, 9555-9555.	1.6	2
56	Outcomes of elderly treated with pembrolizumab for metastatic melanoma comparing with younger patients.. Journal of Clinical Oncology, 2018, 36, e21508-e21508.	1.6	1
57	HORIZON: A French descriptive cohort of 663 patients treated for melanoma with pembrolizumab with a focus on the mucosal subgroup (n=59).. Journal of Clinical Oncology, 2018, 36, 9563-9563.	1.6	0
58	Elderly patientâ€™s tolerance and efficacy for MAP-kinase inhibitors in a French melanoma real-life cohort.. Journal of Clinical Oncology, 2018, 36, e21536-e21536.	1.6	0
59	Horizon: An ambispective study of 663 patients who initiated pembrolizumab for advanced melanoma within the French early access program.. Journal of Clinical Oncology, 2018, 36, e21519-e21519.	1.6	0
60	Discontinuation of anti-PD-1 mAb after complete response in advanced melanoma pts.. Journal of Clinical Oncology, 2018, 36, e21549-e21549.	1.6	1
61	Immune checkpoint inhibitors and stereotactic radiosurgery (SRS) in melanoma brain metastases.. Journal of Clinical Oncology, 2018, 36, e21523-e21523.	1.6	0
62	Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies. Blood, 2018, 132, 2412-2412.	1.4	0
63	Sensitivity and specificity of BP180 NC16A enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis. Journal of the American Academy of Dermatology, 2017, 76, 560-562.	1.2	27
64	Reply to â€œClinical and therapeutic implications of <i>BRAF</i> mutation heterogeneity in metastatic melanomaâ€ by Mesbah Ardakani etÂal.. Pigment Cell and Melanoma Research, 2017, 30, 498-500.	3.3	3
65	Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 863-873.	10.7	561
66	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. Oncolmmunology, 2017, 6, e1338237.	4.6	47
67	Variation of mutant allele frequency in NRAS Q61 mutated melanomas. BMC Dermatology, 2017, 17, 9.	2.1	19
68	Primary medical therapy for BRAFV600E-mutant melanoma brain metastasesâ€is this good enough? â€ Authors' reply. Lancet Oncology, The, 2017, 18, e509.	10.7	3
69	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline â€ Update 2016. European Journal of Cancer, 2016, 63, 201-217.	2.8	330
70	Effectiveness and Safety of Vemurafenib as Monotherapy in Unresectable or Metastatic Melanoma from an Academic Database: Real World Data to Strengthen Evidence for Payer. Value in Health, 2016, 19, A762-A763.	0.3	0
71	First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma. British Journal of Cancer, 2016, 114, 1199-1205.	6.4	30
72	Increase inNRASmutant allele percentage during metastatic melanoma progression. Experimental Dermatology, 2016, 25, 472-474.	2.9	8

#	ARTICLE	IF	CITATIONS
73	Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). <i>Annals of Oncology</i> , 2016, 27, 1947.	1.2	21
74	Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy. <i>New England Journal of Medicine</i> , 2016, 375, 296-297.	27.0	86
75	Reply to the letter to the editor "Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance"™ by Funck-Brentano et al.. <i>Annals of Oncology</i> , 2016, 27, 364-365.	1.2	6
76	Immunotherapy-treated melanoma brain metastases within the French national cohort, MelBase.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9556-9556.	1.6	2
77	Frequent allelic imbalance in <i>NRAS</i> mutant melanomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9578-9578.	1.6	0
78	Melapred: first susceptibility test to sporadic melanoma in daily dermatological practice.. <i>Journal of Clinical Oncology</i> , 2016, 34, e21056-e21056.	1.6	0
79	Relapsing pneumonitis due to two distinct inhibitors of the MAPK/ERK pathway: report of a case. <i>BMC Cancer</i> , 2015, 15, 732.	2.6	7
80	Re: High nevus counts confer a favorable prognosis in melanoma patients by <i>S</i> ribero and coauthors, published in the <i>International Journal of Cancer</i> , 2015 (online 21 march 2015). <i>International Journal of Cancer</i> , 2015, 137, 3006-3007.	5.1	5
81	Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group. <i>British Journal of Dermatology</i> , 2015, 173, 1015-1023.	1.5	11
82	Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 1989-2007.	2.8	404
83	Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 2604-2608.	2.8	109
84	Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma. <i>European Journal of Cancer</i> , 2015, 51, 1780-1793.	2.8	24
85	Immunohistochemistry as a potential tool for routine detection of the NRAS Q61R mutation in patients with metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 786-793.	1.2	37
86	Variations of BRAF mutant allele percentage in melanomas. <i>BMC Cancer</i> , 2015, 15, 497.	2.6	36
87	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 2396-2403.	2.8	320
88	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance. <i>Annals of Oncology</i> , 2015, 26, 1470-1475.	1.2	46
89	Genes involved in the <i>WNT</i> and vesicular trafficking pathways are associated with melanoma predisposition. <i>International Journal of Cancer</i> , 2015, 136, 2109-2119.	5.1	27
90	Detection of <i>BRAF</i> p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 71-75.	2.5	57

#	ARTICLE	IF	CITATIONS
91	Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France. <i>JAMA Dermatology</i> , 2014, 150, 535.	4.1	80
92	Sentinel Node Status and Immunosuppression: Recurrence Factors in Localized Merkel Cell Carcinoma. <i>Acta Dermato-Venereologica</i> , 2014, 95, 835-40.	1.3	12
93	A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 97, 29-32.	2.8	19
94	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the <scp>TRANSIT</scp> randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.5	37
95	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014, 170, 425-434.	1.5	24
96	Phase II multicentric uncontrolled national trial assessing the efficacy of nilotinib in the treatment of advanced melanomas with c-KIT mutation or amplification.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9032-9032.	1.6	4
97	Vitamin D level at diagnosis and its variation during follow-up as prognostic factor of cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9057-9057.	1.6	0
98	Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: Impact on tumor response and tolerance.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9016-9016.	1.6	0
99	Medical students and sun prevention: knowledge and behaviours in France. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e247-51.	2.4	33
100	Evaluation of tourists'™ UV exposure in Paris. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e294-304.	2.4	16
101	Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. <i>British Journal of Dermatology</i> , 2013, 169, 579-586.	1.5	141
102	Projected changes in clear-sky erythemal and vitamin D effective UV doses for Europe over the period 2006 to 2100. <i>Photochemical and Photobiological Sciences</i> , 2013, 12, 1053-1064.	2.9	22
103	Detection of BRAF p.V600E Mutations in Melanomas. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 94-100.	2.8	144
104	Rapidly growing pancreatic ductal adenocarcinoma in a patient with metastatic melanoma and harbouring CDKN2A germline mutation. <i>Melanoma Research</i> , 2013, 23, 241.	1.2	7
105	Counselling on sun protection, a survey of French paediatricians. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e424-7.	2.4	3
106	Understanding recurrent herpes labialis management and impact on patients'™ quality of life: the HERPESCOPE study. <i>European Journal of Dermatology</i> , 2013, 23, 491-499.	0.6	9
107	Personal melanoma risk awareness versus intrinsic risk.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9069-9069.	1.6	0
108	Focal 3D conformal high-dose hypofractionated radiotherapy for brain metastases. <i>Melanoma Research</i> , 2012, 22, 406-409.	1.2	2

#	ARTICLE	IF	CITATIONS
109	Efficacy of Mohs Micrographic Surgery for the Treatment of Dermatofibrosarcoma Protuberans. Archives of Dermatology, 2012, 148, 1055.	1.4	119
110	Guidelines for the diagnosis and treatment of Merkel cell carcinoma. Cutaneous Oncology Group of the French Society of Dermatology. European Journal of Dermatology, 2012, 22, 375-379.	0.6	31
111	Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes. Annals of Surgical Oncology, 2012, 19, 4314-4321.	1.5	91
112	Interest of corrective makeup in the management of patients in dermatology. Clinical, Cosmetic and Investigational Dermatology, 2012, 5, 123.	1.8	45
113	Incomplete efficacy of 5-aminolevulinic acid (5 ALA) photodynamic therapy in the treatment of widespread extramammary Paget's disease. Photodermatology Photoimmunology and Photomedicine, 2012, 28, 53-55.	1.5	18
114	Vemurafenib (V) in BRAF V600E metastatic melanoma (mM): Analysis of 507 patients (pts) enrolled in the French temporary authorization for use (ATU).. Journal of Clinical Oncology, 2012, 30, 8591-8591.	1.6	2
115	Sun exposure profile in the French population: Results of the EDIFICE melanoma survey.. Journal of Clinical Oncology, 2012, 30, 1566-1566.	1.6	1
116	Comparison of sun protection modalities in parents and children.. Journal of Clinical Oncology, 2012, 30, 8601-8601.	1.6	1
117	Prognostic value of BRAFV600 mutations in melanoma patients after resection of metastatic lymph nodes.. Journal of Clinical Oncology, 2012, 30, 8540-8540.	1.6	1
118	Assessment of tyrosinase variants and skin cancer risk in a large cohort of French subjects. Journal of Dermatological Science, 2011, 64, 127-133.	1.9	17
119	A case-control study of cutaneous signs in adult patients with Marfan disease: Diagnostic value of striae. Journal of the American Academy of Dermatology, 2011, 64, 290-295.	1.2	24
120	Are sunscreens luxury products?. Journal of the American Academy of Dermatology, 2011, 65, e73-e79.	1.2	24
121	Validity of satellite measurements used for the monitoring of UV radiation risk on health. Atmospheric Chemistry and Physics, 2011, 11, 13377-13394.	4.9	26
122	Compliance with indoor tanning advertising regulations in France. British Journal of Dermatology, 2011, 164, 880-882.	1.5	7
123	Outdoor sports and risk of ultraviolet radiation-related skin lesions in children: evaluation of risks and prevention. British Journal of Dermatology, 2011, 165, 360-367.	1.5	43
124	Parents' attitudes related to melanocytic nevus count in children. European Journal of Cancer Prevention, 2010, 19, 472-477.	1.3	5
125	Interactions between ultraviolet light exposure and DNA repair gene polymorphisms may increase melanoma risk. British Journal of Dermatology, 2010, 162, 891-893.	1.5	5
126	GLI2-Mediated Melanoma Invasion and Metastasis. Journal of the National Cancer Institute, 2010, 102, 1148-1159.	6.3	149

#	ARTICLE	IF	CITATIONS
127	No Correlation between the Molecular Subtype of COL1A1- <i>PDGFB</i> Fusion Gene and the Clinico-Histopathological Features of Dermatofibrosarcoma Protuberans. <i>Journal of Investigative Dermatology</i> , 2010, 130, 904-907.	0.7	33
128	Comparison between UV index measurements performed by research-grade and consumer-products instruments. <i>Photochemical and Photobiological Sciences</i> , 2010, 9, 459-463.	2.9	30
129	Neonatal Blue-Light Phototherapy Does Not Increase Nevus Count in 9-Year-Old Children. <i>Pediatrics</i> , 2009, 123, e896-e900.	2.1	27
130	Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. <i>British Journal of Dermatology</i> , 2009, 161, 904-909.	1.5	33
131	Bullous DRESS in a patient on strontium ranelate. <i>Clinical and Experimental Dermatology</i> , 2009, 34, e349-e350.	1.3	9
132	A Comparison of Two Regimens of Topical Corticosteroids in the Treatment of Patients with Bullous Pemphigoid: A Multicenter Randomized Study. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1681-1687.	0.7	207
133	Projet r�seau cancers cutan�s rares K-CUR. <i>Oncologie</i> , 2008, 10, 409-410.	0.7	0
134	Variants of the <i>MATP</i> / <i>SLC45A2</i> gene are protective for melanoma in the French population. <i>Human Mutation</i> , 2008, 29, 1154-1160.	2.5	61
135	Tacrolimus ointment, an interesting adjunctive therapy for childhood linear IgA bullous dermatosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 364-365.	2.4	12
136	Escitalopram photo-induced erythroderma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008, 22, 1015-1017.	2.4	9
137	The contribution of high-resolution ultrasonography in preoperatively detecting sentinel-node metastases in melanoma patients. <i>Melanoma Research</i> , 2007, 17, 233-237.	1.2	33
138	Tacrolimus pommade, une alternative � la corticoth�rapie locale dans la dermatose � IgA lin�aire. <i>Annales De Dermatologie Et De Venereologie</i> , 2007, 134, 608.	1.0	0
139	Melanoma susceptibility and progression: Association study between polymorphisms of the chemokine (CCL2) and chemokine receptors (CX3CR1, CCR5). <i>Journal of Dermatological Science</i> , 2007, 46, 72-76.	1.9	6
140	A French CDK4-positive melanoma family with a co-inherited EDNRB mutation. <i>Journal of Dermatological Science</i> , 2007, 46, 61-64.	1.9	18
141	Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report. <i>European Journal of Dermatology</i> , 2007, 17, 325-31.	0.6	36
142	MC1R and PTCH Gene Polymorphism in French Patients with Basal Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1510-1517.	0.7	67
143	PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. <i>British Journal of Cancer</i> , 2006, 95, 548-553.	6.4	58
144	Ultrasonography Using Simple Diagnostic Criteria vs Palpation for the Detection of Regional Lymph Node Metastases of Melanoma. <i>Archives of Dermatology</i> , 2005, 141, 183-9.	1.4	47

#	ARTICLE	IF	CITATIONS
145	Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma. <i>European Journal of Human Genetics</i> , 2005, 13, 913-920.	2.8	86
146	Response to: Mortality Rate of Bullous Pemphigoid in a US Medical Center. <i>Journal of Investigative Dermatology</i> , 2005, 124, 664-665.	0.7	15
147	Prediction of Survival for Patients With Bullous Pemphigoid. <i>Archives of Dermatology</i> , 2005, 141, 691-8.	1.4	141
148	Association Between Endothelin Receptor B Nonsynonymous Variants and Melanoma Risk. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1297-1301.	6.3	22
149	Améliorations de la chirurgie micrographique de Mohs sur la base de l'expérience du traitement de 235 carcinomes basocellulaires du visage. <i>Annales De Dermatologie Et De Venereologie</i> , 2005, 132, 606-607.	1.0	0
150	Association study of the g.8818A>G polymorphism of the human agouti gene with melanoma risk and pigmentary characteristics in a French population. <i>Journal of Dermatological Science</i> , 2005, 40, 133-136.	1.9	14
151	Treatment of Undifferentiated Vulvar Intraepithelial Neoplasia With 5% Imiquimod Cream. <i>Archives of Dermatology</i> , 2004, 140, 1220-4.	1.4	30
152	Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 1118-1125.	1.6	439
153	Germline mutations of the INK4a-ARF gene in patients with suspected genetic predisposition to melanoma. <i>British Journal of Cancer</i> , 2004, 90, 503-509.	6.4	35
154	Pathologies du système nerveux central associées à la maladie de Cowden. <i>Annales De Dermatologie Et De Venereologie</i> , 2004, 131, 1135.	1.0	0
155	Ultrasonography or palpation for detection of melanoma nodal invasion: a meta-analysis. <i>Lancet Oncology</i> , The, 2004, 5, 673-680.	10.7	120
156	Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. <i>Blood</i> , 2004, 103, 3662-3668.	1.4	139
157	Efficacy of imiquimod on external anogenital warts in HIV-infected patients previously treated by highly active antiretroviral therapy. <i>Aids</i> , 2002, 16, 1438-1440.	2.2	14
158	Is Dermoscopy (Epiluminescence Microscopy) Useful for the Diagnosis of Melanoma?. <i>Archives of Dermatology</i> , 2001, 137, 1343-50.	1.4	418
159	Clinical and Virologic Characterization of Acyclovir-Resistant Varicella-Zoster Viruses Isolated from 11 Patients with Acquired Immunodeficiency Syndrome. <i>Clinical Infectious Diseases</i> , 2001, 33, 2061-2067.	5.8	77
160	Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. <i>Aids</i> , 2000, 14, 987-993.	2.2	107
161	Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. <i>European Journal of Immunology</i> , 2000, 30, 2281-2289.	2.9	47
162	Lipodystrophy associated with protease inhibitors. <i>British Journal of Dermatology</i> , 2000, 142, 496-500.	1.5	47

#	ARTICLE	IF	CITATIONS
163	A double-blind, randomized study assessing the equivalence of valacyclovir 1000 mg once daily versus 500 mg twice daily in the episodic treatment of recurrent genital herpes. <i>Journal of Antimicrobial Chemotherapy</i> , 1999, 44, 525-531.	3.0	29
164	Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid. <i>Aids</i> , 1998, 12, 2169-2176.	2.2	38
165	Recurrent Erythema Multiforme Unresponsive to Acyclovir Prophylaxis and Responsive to Valacyclovir Continuous Therapy. <i>Archives of Dermatology</i> , 1998, 134, 876-877.	1.4	32
166	Lipschutz's genital ulceration: a manifestation of Epstein-Barr virus primary infection. <i>British Journal of Dermatology</i> , 1996, 135, 663-665.	1.5	38
167	Acute Generalized Exanthematous Pustulosis Induced by Hydroxychloroquine. <i>Dermatology</i> , 1996, 193, 70-71.	2.1	33
168	Value of fine-needle aspiration in infectious cellulitis. <i>Archives of Dermatology</i> , 1996, 132, 842-3.	1.4	3
169	Regression of sclerodermatous skin lesions in a patient with carcinoid syndrome treated by octreotide. <i>Archives of Dermatology</i> , 1995, 131, 1207-1209.	1.4	13
170	Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. <i>Archives of Dermatology</i> , 1995, 131, 669-72.	1.4	9
171	Magnetic resonance imaging in adults presenting with severe acute infectious cellulitis. <i>Archives of Dermatology</i> , 1994, 130, 1150-8.	1.4	9
172	Sarcoidosis Associated with Leucocytoclastic Vasculitis. <i>Dermatology</i> , 1993, 187, 50-53.	2.1	14
173	Evolving Pattern of Drug-Induced Toxic Epidermal Necrolysis. <i>Dermatology</i> , 1993, 186, 32-37.	2.1	76
174	Pustulotic arthroostitis triggered by echovirus 9?. <i>Journal of Rheumatology</i> , 1993, 20, 1992-3.	2.0	0
175	Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. <i>Journal of the American Academy of Dermatology</i> , 1992, 26, 567-574.	1.2	166
176	Vaccinia from recombinant virus expressing HIV genes. <i>Lancet, The</i> , 1991, 337, 1034-1035.	13.7	37
177	Nonsteroidal anti-inflammatory drugs in cellulitis: a cautionary note. <i>Archives of Dermatology</i> , 1991, 127, 1845-6.	1.4	3
178	Toxic epidermal necrolysis (Lyell syndrome). <i>Journal of the American Academy of Dermatology</i> , 1990, 23, 1039-1058.	1.2	401
179	Failure of warfarin in treatment of calcinosis universalis. <i>American Journal of Medicine</i> , 1988, 84, 795-796.	1.5	54
180	A new method for studying epidermalization in vitro. <i>British Journal of Dermatology</i> , 1986, 114, 91-101.	1.5	90

#	ARTICLE	IF	CITATIONS
181	Lasers, dermal fibroblasts and psoriasis. British Journal of Dermatology, 1986, 115, 744-745.	1.5	3
182	Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro. Science, 1985, 230, 669-672.	12.6	208